Clinical trials: Affective Disorder
Schizophrenia
A Dose-proportionality Study of Five Tablet Strengths of ER OROS Paliperidone
The purpose of this study is to evaluate the dose proportionality of the 3-, 6-, 9-, 12-, and 15-mg tablets of ER OROS paliperidone.
- Trial name
- NCT00796835
- Testing
- ER OROS Paliperidone
- Volunteers
- 50 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder
The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder
This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to assess the efficacy and safety of brexpiprazole as adjunctive therapy in the treatment of Major Depressive Disorder.
- Trial name
- NCT03487198
- Testing
- Brexpiprazole
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Otsuka Beijing Research Institute
Major Depressive Disorder
Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India
The purpose of this study is to evaluate the safety and tolerability of flexible doses of vortioxetine (5 - 20 mg/day) over a period of 12 weeks in patients with depression in India
- Trial name
- NCT04288895
- Testing
- Vortioxetine
- Where
- 24 sites in India
- Volunteers
- 400 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Using Voice Biomarkers to Predict the Likelihood of Major Depressive Disorder
Major Depressive Disorder (MDD) is the leading cause of disability worldwide. Depression and anxiety disorders are among the most prevalent of all mental disorders, with an estimated annual prevalence of 9.7% and 18.1%…
- Trial name
- NCT04874077
- Where
- 2 sites in United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Kintsugi Mindful Wellness, Inc.
Major Depressive Disorder, Dysthymia
Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms
The investigators hypothesize that patients receiving citalopram in combination with lithium will have a greater reduction in depressive symptoms than patients receiving citalopram in combination with placebo.
- Conditions
- Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified, Borderline Personality Disorder
- Trial name
- NCT01189812
- Testing
- Lithium Carbonate, Citalopram
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Columbia Northwest Pharmaceuticals
Major Depressive Disorder
Open Label Optimization Study
The goal of this observational study is to demonstrate effectiveness in the treatment of Major Depressive Disorder The primary objective is to assess the effectiveness in the treatment of Major Depressive Disorder using the CGI-I…
- Trial name
- OLO (NCT05819021)
- Testing
- SAINT® Neuromodulation System (NMS)
- Where
- 7 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Magnus Medical
Major Depressive Disorder
A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel
The purpose of this study is to measure how much of the study drugs (clopidogrel and LY2216684) reach the blood stream and how long it takes the body to dispose of them and to determine how clopidogrel and LY2216684 might affect…
- Trial name
- NCT01263093
- Testing
- Clopidogrel, LY2216684
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of sirukumab as adjunctive treatment to antidepressant therapy (monoaminergic antidepressant) where sirukumab (administered as a 50 milligram (mg) subcutaneous (SC) injection…
- Trial name
- NCT02473289
- Testing
- Sirukumab 50 mg
- Where
- 46 sites in United States, Canada and 3 more
- Volunteers
- 193 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder (MDD)
A Study to Evaluate Efficacy and Safety of GW117 Tablets in Major Depressive Disorder
The study aims to evaluate the efficacy and safety of GW117 Tablets compared to placebo in adults participants with MDD over a period of 8 weeks.
- Trial name
- NCT06796868
- Testing
- GW117 Tablets
- Where
- 17 sites in China
- Volunteers
- 280 people
- Sponsor
- Beijing Greatway Pharmaceutical Technology Co.,Ltd.
Bipolar Depression
A Phase III Study of SM-13496 in Patients With Bipolar I Depression.
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with Bipolar I Depression.
- Trial name
- NCT01986101
- Testing
- SM-13496
- Where
- 8 sites in Japan, Lithuania and 6 more
- Volunteers
- 525 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Major Depressive Disorder (MDD
A Study of ONO-1110 in Patients With Major Depressive Disorder
To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Major Depressive Disorder
- Trial name
- NCT06792136
- Testing
- ONO-1110
- Where
- 29 sites in Japan
- Volunteers
- 103 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Treatment-resistant Depression
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) participants from a prior antidepressant treatment (to which they have not responded) to either intranasal…
- Trial name
- TRANSFORM-1 (NCT02417064)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 90 sites in United States, Belgium and 7 more
- Volunteers
- 346 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
The main research hypothesis for this study is that, among patients with Major Depressive Disorder (MDD) who have responded inadequately to treatment with SSRIs or SNRIs, the degree of improvement, as measured by the change from…
- Trial name
- NCT01318434
- Testing
- EB-1010 25mg BID, SSRI Active, EB-1010 50mg BID
- Where
- 43 sites in United States
- Volunteers
- 342 people
- Sponsor
- Euthymics BioScience, Inc.
Major Depressive Disorder
Study to Assess the Safety and Effectiveness of NMRA-335140-501
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD).
- Trial name
- NCT06029439
- Testing
- NMRA-335140
- Where
- 178 sites in United States, Brazil and 9 more
- Volunteers
- 904 people
- Sponsor
- Neumora Therapeutics, Inc.
Bipolar I Disorder, Bipolar II Disorder
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how safe and effective ABBV-932 is in treating participants with bipolar I or II…
- Trial name
- CANTO (NCT06605599)
- Testing
- ABBV-932
- Where
- 40 sites in United States, Japan and 1 more
- Volunteers
- 161 people
- Sponsor
- AbbVie
Treatment Resistant Depression
Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)
The main purpose of this study is to assess the efficacy and safety of daily and intermittent dosing of MK-1942 compared to placebo among participants with Treatment-Resistant Depression (TRD) on a stable course of antidepressant…
- Trial name
- NCT04663321
- Testing
- MK-1942
- Where
- 45 sites in United States
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Bipolar Disorder
A Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy Subjects
The purpose of this study is to investigate the effect of drug A on its own and when it is given in combination with drug B on markers of brain activity. The study will 1.
- Trial name
- NCT00907985
- Testing
- Vofopitant, Lamotrigine
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Postpartum Depression
A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 micrograms per kilogram per hour (μg/kg/h) for 60 hours reduces depressive symptoms in participants with severe postpartum…
- Trial name
- NCT02942004
- Testing
- SAGE-547 60 μg/kg/h, SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 138 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Bipolar Disorder, Bipolar Depression
Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy
Prospective, open-label, controlled (active comparator), randomized study of 8 weeks follow-up for the evaluation of the efficacy of extended release quetiapine (quetiapine XR) versus Sertraline in addition to previous mood…
- Trial name
- NCT00857584
- Testing
- Extended release quetiapine (quetiapine XR), Sertraline, adequate mood stabilizer
- Where
- 4 sites in Spain
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Depressive Disorder
A Study Of New Medicine (GSK 372475) For The Treatment Of Depression
To evaluate the efficacy, safety, and tolerability of GSK372475 compared with placebo in the treatment of outpatient subjects with Major Depressive Disorder (MDD)
- Trial name
- NCT00448058
- Testing
- GSK372475, venlafaxine
- Where
- 42 sites in Australia, Belgium and 10 more
- Volunteers
- 396 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.